DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

10,300

Employees10,300

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

10,300

Employees10,300

DXCM Key Statistics

Market cap

28.30B

Market cap28.30B

Price-Earnings ratio

40.65

Price-Earnings ratio40.65

Dividend yield

—

Dividend yield—

Average volume

5.65M

Average volume5.65M

High today

$73.59

High today$73.59

Low today

$72.23

Low today$72.23

Open price

$72.41

Open price$72.41

Volume

3.27M

Volume3.27M

52 Week high

$93.25

52 Week high$93.25

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $72.42. The company's market cap stands at 28.3B, with a P/E ratio of 40.65.

As of 2026-02-02, DexCom(DXCM) stock has fluctuated between $72.23 and $73.59. The current price stands at $72.42, placing the stock +0.3% above today's low and -1.6% off the high.

The DexCom(DXCM)'s current trading volume is 3.27M, compared to an average daily volume of 5.65M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.

DXCM News

Simply Wall St 21h

What DexCom's Strong Q4 Beat and Margin Guidance Means For Shareholders

In late January 2026, DexCom reported preliminary fourth-quarter results that surpassed consensus expectations, with year-over-year revenue growth across both U...

Simply Wall St 3d

DexCom Faces Split Analyst Views As Competition Pressures Core CGM Markets

Barclays downgraded DexCom on concerns about rising competition in its core insulin intensive market segments. Other major analysts maintained more positive ou...

Simply Wall St 4d

Assessing DexCom Valuation After Barclays Downgrade On Rising CGM Competition

DexCom (DXCM) is back in focus after Barclays downgraded the stock to Underweight, citing intensifying competition in its core insulin-intensive markets project...

Analyst ratings

82%

of 33 ratings

Buy

81.8%

Hold

15.2%

Sell

More DXCM News

Nasdaq 4d

Interesting DXCM Put And Call Options For March 13th

Investors in DexCom Inc (Symbol: DXCM) saw new options become available today, for the March 13th expiration. At Stock Options Channel , our YieldBoost formula...

Simply Wall St 6d

Is Dexcom Pricing Reflect Long Term Potential After Continuous Glucose Monitoring Focus?

If you are wondering whether DexCom's current share price reflects its long term potential, this article walks through what the numbers are actually saying abou...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.